Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin Limited    LUPIN   INE326A01037

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Lupin Limited : Lupin Looking for Acquisitions of up to $500 Million in US

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/01/2012 | 12:39pm CET

--Looking for buys in skin care, eye care, respiratory and women's health products

--Trying to expand pipeline of low-competition generic drugs for US market

(Adds executive's comments in 7th, 9th, 12th and 13th paragraphs, background and context elsewhere)

By Rumman Ahmed

BANGALORE--Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

The U.S. is Lupin's primary growth market, accounting for 35% of its sales.

The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.

"We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta recently told Dow Jones Newswires.

Unlike most of its local rivals, Lupin's business model for the world's largest pharmaceuticals market is not limited to selling drug copies: It also sells branded products like antibiotic Suprax and anti-cholesterol drug Antara. While the branded products contribute about 25% of Lupin's U.S. revenue, they make up a larger share of its profit.

Lupin is looking for acquisitions to revive the momentum in the branded-products business at a time when existing brands are likely to come up against generic competition.

The company would prefer acquisitions in the areas of skin care, eye care, respiratory and women's health products, which are more in line with the company's commercial infrastructure in the U.S., Ms. Gupta said.

The company's 160-person sales force in the U.S. is focused on selling branded products to the pediatric and primary-care market segments.

Ms. Gupta, who also heads Lupin's U.S. unit, said Lupin had mulled acquiring eye-care company ISTA Pharmaceuticals Inc., but found it wasn't a "good fit."

Eye-products maker Bausch & Lomb Inc. purchased ISTA for about $500 million in cash in a deal that closed in June.

Lupin's previous acquisitions in the U.S. were much smaller in comparison. In 2009 it paid $38.61 million to bankrupt Oscient Pharmaceuticals Corp. for Antara, and acquired AllerNaze nasal spray from U.S.-based Collegium Pharmaceutical Inc. for an undisclosed amount.

As for its generic drugs business, Lupin is trying to move its pipeline to products that are exclusive and face less competition, Ms. Gupta said.

Lupin has already applied to sell generic versions of about 31 oral contraceptive products and some eye treatments. It has also filed the first generic drug application with the U.S. regulator for a skin care product in the January-March period, she added.

Benefits from selling these drugs, which have relatively high entry barriers and offer higher-than-average margins, are expected to kick in from the fiscal year starting next April.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUPIN LIMITED
03/18 LUPIN : Pharma & Healthcare Newsletter – March 13 to March 17, 2017
03/16 LUPIN : launches Generic Minastrin® 24 Fe chewable tablets in the US
03/07 LUPIN : launches generic Paxil CR tablets in the US
03/04 LUPIN : Pharma & Healthcare Newsletter – February 27 to March 3, 2017
03/04 LUPIN : receives FDA approval for Generic Suprep Bowel Prep Kit
03/03 LUPIN : Launches Generic Pristiq Tablets in the US
03/03 LUPIN : Launches anti-depressant drug in us market
03/02 LUPIN : Launches solution for skin inflammation
03/01 LUPIN : launches generic Temovate Clobetasol Propionate Scalp application in US
02/27 LUPIN : subsidiary Kyowa gets right to distribute quetiapine fumarate tablets in..
More news
Sector news : Pharmaceuticals - NEC
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( INR)
Sales 2017 174 760 M
EBIT 2017 38 551 M
Net income 2017 28 006 M
Debt 2017 50 161 M
Yield 2017 0,59%
P/E ratio 2017 23,19
P/E ratio 2018 20,27
EV / Sales 2017 4,08x
EV / Sales 2018 3,50x
Capitalization 662 914 M
More Financials
Chart LUPIN LIMITED
Duration : Period :
Lupin Limited Technical Analysis Chart | LUPIN | INE326A01037 | 4-Traders
Full-screen chart
Technical analysis trends LUPIN LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 43
Average target price 1 716  INR
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita Gupta Sharma Chief Executive Officer & Executive Director
Desh Bandhu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Vijay Laxman Kelkar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN LIMITED-2.12%10 133
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
MERCK & CO., INC.7.86%174 344
More Results